Only in Titles

Search results for: Assay

paperclip

#33086452   // To Up

[Clinicopathological features of Caroli disease/Caroli syndrome: an analysis of 21 cases].

To summarize and compare clinicopathological features of Caroli disease and Caroli syndrome. A total of 21 patients diagnosed with Caroli disease or Caroli syndrome in Beijing Friendship Hospital, Capital Medical University, from January 2015 to December 2018 were included. Through the clinical manifestations and comparative analysis of the differences between different clinical types, the liver pathological features of these patients were described. Of all patients included, 8 were male and 13 were female, and the medium age was 13.5 year old. The initial symptom was fever in 6 cases (28.6%), gastrointestinal bleeding in 6 cases (28.6%) and hepatosplenomegaly in 9 cases (42.8%). Caroli disease accounted for 6 cases (28.6%) and Caroli syndrome 15 cases (71.4%). The total bilirubin [6.7 (4.7, 15.0) vs 16.0(10.9, 33.0)μmol/L] and direct bilirubin [1.3(0.9,6.4)vs 3.5(2.7, 16.2)μmol/L] were significantly lower in Caroli disease group in comparison to those in Caroli syndrome group(both 0.05). The hemoglobin [117.0 (106.0, 126.2) vs 85.0 (74.0, 103.0) g/L] and platelet count [286.0 (149.8, 467.5)×10(9)/L vs 76.1(55.0,123.0)×10(9)/L] in Caroli disease group were significantly higher than those in Caroli syndrome group (both 0.05). There were 10 patients (47.6%) who underwent liver transplantation. Child-Pugh-Turcotte Score (liver function reserve) were significantly higher than that in the non-liver transplantation group[8.0(8.0, 10.2)vs 5.0 (5.0, 6.0), 0.05]. Early symptoms of Caroli disease/Caroli syndrome are atypical and prone to misdiagnosis and misdiagnosis. The diagnosis is usually based on pathology and may be supplemented by laboratory examination and imaging analysis.
J Li, L W Liu, J Luo, J X Liu, X J Liu, Z J Zhu, L Y Sun, X Y Zhao

1615 related Products with: [Clinicopathological features of Caroli disease/Caroli syndrome: an analysis of 21 cases].

1 module

Related Pathways

paperclip

#33086443   // To Up

An Analysis of Myocardial Efficiency in Patients with Severe Asymptomatic Mitral Regurgitation.

It is difficult to determine left ventricular systolic performance in patients with severe mitral regurgitation (MR) since left ventricular ejection fraction (EF) could be preserved until the end stages of the disease. Myocardial efficiency (MEf) describes the amount of external work (EW) done by the left ventricle per unit of oxygen consumed (mVO₂). In the present study, we aimed to investigate MEf in patients with asymptomatic severe MR using a novel echocardiographic method.
Rengin Çetin Güvenç, Emre Aruğaslan, Tolga Sinan Güvenç, Fatma Özpamuk Karadeniz, Hülya Kaşıkçıoğlu, Neşe Çam

1135 related Products with: An Analysis of Myocardial Efficiency in Patients with Severe Asymptomatic Mitral Regurgitation.

100ug100 μg1 Set1 Set1 Set100 μg1 Set500 100ug50ul (1mg/ml)100 μg

Related Pathways

paperclip

Error loading info... Pleas try again later.
paperclip

#33086431   2020/10/21 To Up

Assessment of clinicopathological and prognostic relevance of BMI-1 in patients with colorectal cancer: a meta-analysis.

B-cell-specific Moloney leukemia virus insertion site 1 (BMI-1) is one of the stemness markers. The prognostic and clinicopathological effects of BMI-1 expression in colorectal cancer (CRC) have been in dispute with different studies.
Mona Pourjafar, Pouria Samadi, Manoochehr Karami, Rezvan Najafi

2399 related Products with: Assessment of clinicopathological and prognostic relevance of BMI-1 in patients with colorectal cancer: a meta-analysis.

100ug Lyophilized100ug Lyophilized100ug Lyophilized100ug100ug100ug Lyophilized

Related Pathways

paperclip

#33086429   2020/10/21 To Up

The feasibility of polypill for cardiovascular disease prevention in Asian Population.

P
Apichard Sukonthasarn, Yook-Chin Chia, Ji-Guang Wang, Jennifer Nailes, Peera Buranakitjaroen, Huynh Van Minh, Narsingh Verma, Satoshi Hoshide, Jinho Shin, Yuda Turana, Jam Chin Tay, Boon Wee Teo, Saulat Siddique, Jorge Sison, Yu-Qing Zhang, Tzung-Dau Wang, Chen-Huan Chen, Kazuomi Kario

1300 related Products with: The feasibility of polypill for cardiovascular disease prevention in Asian Population.

500 tests500 MG96 tests95 Tests / Kit96 tests500 tests

Related Pathways

    No related Items
paperclip

#33086428   2020/10/21 To Up

Regression calibration to correct correlated errors in outcome and exposure.

Measurement error arises through a variety of mechanisms. A rich literature exists on the bias introduced by covariate measurement error and on methods of analysis to address this bias. By comparison, less attention has been given to errors in outcome assessment and nonclassical covariate measurement error. We consider an extension of the regression calibration method to settings with errors in a continuous outcome, where the errors may be correlated with prognostic covariates or with covariate measurement error. This method adjusts for the measurement error in the data and can be applied with either a validation subset, on which the true data are also observed (eg, a study audit), or a reliability subset, where a second observation of error prone measurements are available. For each case, we provide conditions under which the proposed method is identifiable and leads to consistent estimates of the regression parameter. When the second measurement on the reliability subset has no error or classical unbiased measurement error, the proposed method is consistent even when the primary outcome and exposures of interest are subject to both systematic and random error. We examine the performance of the method with simulations for a variety of measurement error scenarios and sizes of the reliability subset. We illustrate the method's application using data from the Women's Health Initiative Dietary Modification Trial.
Pamela A Shaw, Jiwei He, Bryan E Shepherd

2030 related Products with: Regression calibration to correct correlated errors in outcome and exposure.

101 mg100 96 wells (1 kit)1 mg

Related Pathways

paperclip

#33086427   2020/10/21 To Up

Usefulness of ankle-brachial index calculated using diastolic blood pressure for prediction of mortality in patients with acute myocardial infarction.

A low ankle-brachial index (ABI) calculated using systolic blood pressure (SBP) (ABIsbp) is associated with poor cardiovascular outcome in patients with acute myocardial infarction (AMI). ABI is always calculated using SBP clinically. However, there was no study investigating ABI calculated using mean artery pressure (MAP)(ABImap) and diastolic blood pressure (DBP)(ABIdbp) for mortality prediction in AMI patients. Therefore, our study was aimed to investigate the issue. 199 AMI patients were enrolled. Different ABIs were measured by an ABI-form device. The median follow-up to mortality was 64 months. There were 40 cardiovascular and 137 all-cause mortality. The best cutoff values of ABImbp and ABIdbp for mortality prediction were 0.91 and 0.78, respectively. After multivariate analysis, only ABIdbp and ABIdbp < 0.78 could predict cardiovascular mortality (P ≤ .047). However, all of six ABI parameters, including ABIsbp, ABImap, ABIdbp, ABIsbp < 0.90, ABImap < 0.91, and ABIdbp < 0.78, could predict all-cause mortality (P ≤ .048). In a direct comparison of six ABI models for prediction of all-cause mortality, basic model + ABIdbp <0.78 had the highest predictive value (P ≤ .025). In conclusion, only ABIdbp and ABIdbp < 0.78 could predict cardiovascular and all-cause mortality after multivariate analysis in our study. Furthermore, when adding into a basic model, ABIdbp < 0.78 had the highest additively predictive value for all-cause mortality in the six ABI parameters. Hence, calculation of ABI using DBP except SBP might provide an extra benefit in prediction of cardiovascular and all-cause mortality in AMI patients.
Po-Chao Hsu, Wen-Hsien Lee, Cheng-An Chiu, Ying-Chih Chen, Ching-Tang Chang, Wei-Chung Tsai, Chun-Yuan Chu, Tsung-Hsien Lin, Wen-Chol Voon, Wen-Ter Lai, Sheng-Hsiung Sheu, Ho-Ming Su

1202 related Products with: Usefulness of ankle-brachial index calculated using diastolic blood pressure for prediction of mortality in patients with acute myocardial infarction.

500 MG1600 100 G250 mg 5 G 1 G 100 UG 1 G

Related Pathways

paperclip

#33086410   2020/10/21 To Up

[Beta-hydroxybutyrate measurements with the GlucoMen®LX Plus in the diagnosis of diabetic ketoacidosis in dogs and cats].

The measurement of beta-hydroxybutyrate (BOHB) carries high significance for the diagnosis, prognosis as well as treatment decisions in canine and feline diabetic ketoacidosis. The aim of this study was to establish clinically usable cut-off values for BHOB measurements in dogs and cats using the glucometer GlucoMenLX Plus.
Fabian Schramm, Mirjam Weiß, Dorothee Dahlem

2168 related Products with: [Beta-hydroxybutyrate measurements with the GlucoMen®LX Plus in the diagnosis of diabetic ketoacidosis in dogs and cats].

1100ug Lyophilized100ug100 μg

Related Pathways

paperclip

#33086402   2020/10/21 To Up

Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials.

Thrombotic cardiovascular disease (myocardial infarction [MI], stroke, and venous thromboembolism [VTE]) remains a major cause of death and disability. Sulodexide is an oral glycosaminoglycan containing heparan sulfate and dermatan sulfate. We conducted a systematic review and meta-analysis to determine the cardiovascular efficacy, and safety of sulodexide versus control in randomized controlled trials (RCTs). We searched MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials for RCTs reporting cardiovascular outcomes in patients receiving sulodexide versus control (placebo or no treatment). Outcomes included all-cause mortality, cardiovascular mortality, MI, stroke, deep vein thrombosis (DVT), pulmonary embolism, and bleeding. We used inverse variance random-effects models with odds ratio (OR) as the effect measure. After screening 360 records, 6 RCTs including 7,596 patients (median follow-up duration: 11.6 months) were included. Patients were enrolled for history of MI, VTE, peripheral arterial disease, or cardiovascular risk factors plus nephropathy. Use of sulodexide compared with control was associated with reduced odds of all-cause mortality (OR 0.67, 95% confidence interval [CI] 0.52-0.85,  = 0.001), cardiovascular mortality (OR 0.44, 95% CI 0.22-0.89,  = 0.02), and MI (OR 0.70, 95% CI 0.51-0.96,  = 0.03), and nonsignificantly reduced odds of stroke (OR 0.78, 95% CI 0.45-1.35,  = 0.38). Sulodexide was associated with significantly reduced odds of VTE (OR 0.44, 95% CI 0.24-0.81,  = 0.008), including DVT (OR 0.41, 95% CI 0.26-0.65,  < 0.001), but not pulmonary embolism (OR 0.92, 95% CI 0.40-2.15,  = 0.86). Bleeding events were not significantly different in the two groups (OR 1.14, 95% CI 0.47-2.74,  = 0.48). In six RCTs across a variety of clinical indications, use of sulodexide compared with placebo or no treatment was associated with reduced odds of all-cause mortality, cardiovascular mortality, MI, and DVT, without a significant increase in bleeding. Additional studies with this agent are warranted.
Behnood Bikdeli, Saurav Chatterjee, Ajay J Kirtane, Sahil A Parikh, Giuseppe M Andreozzi, Nihar R Desai, Dominic P Francese, C Michael Gibson, Gregory Piazza, Samuel Z Goldhaber, John W Eikelboom, Harlan M Krumholz, Gregg W Stone

1000 related Products with: Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials.

1 mg100ul100ul1,000 tests50 ug 25 mg1000 tests100ug 5 G100ug2.5 mg

Related Pathways

paperclip

#33086400   2020/10/21 To Up

Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.

Emicizumab, a bispecific monoclonal antibody, bridges activated factor IX (FIXa) and FX, replacing the function of missing FVIIIa to restore effective hemostasis in persons with hemophilia A (PwHA). Here we assess pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers in PwHA with FVIII inhibitors in the Phase III HAVEN 1 study (NCT02622321). Blood samples from 112 PwHA receiving 1.5 mg/kg once-weekly subcutaneous emicizumab were analyzed at central laboratories. Emicizumab concentrations for PK analysis were measured via validated immunoassay. PD effects were assessed using FVIII chromogenic activity assay containing human factors (Hyphen Biophen FVIII:C), and by FXIa-triggered thrombin generation (TG). Activated partial thromboplastin time (aPTT), prothrombin time (PT), antigen levels of FIX and FX, fibrinogen, D-dimer, and prothrombin fragment 1.2 (PF1.2) levels were determined. Emicizumab trough concentrations ≥ 50 µg/mL were maintained throughout the study. FVIII-like activity and TG (peak height) correlated with emicizumab concentrations and remained above 20 U/dL and 100 nM, respectively, with a weekly maintenance dose, theoretically converting persons with severe hemophilia A to a mild disease phenotype. aPTT was normalized at subtherapeutic concentrations of emicizumab. Plasma concentrations of target antigens FIX and FX were not significantly affected by emicizumab treatment; nor were fibrinogen, PT (international normalized ratio), D-dimer, or PF1.2. The PK profile of once-weekly emicizumab in HAVEN 1 provides sustained therapeutic plasma levels, consistent with population PK models. Both the PK profile and the PD and safety biomarkers are consistent with the established efficacy of emicizumab prophylaxis in PwHA with FVIII inhibitors.
Christophe Schmitt, Joanne I Adamkewicz, Jin Xu, Claire Petry, Olivier Catalani, Guy Young, Claude Negrier, Michael U Callaghan, Gallia G Levy

1180 related Products with: Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study.

100ug100ug Lyophilized100ug100ug Lyophilized100ug100ul100ug Lyophilized100ug100ug100ug Lyophilized100ug100ug

Related Pathways